For research use only. Not for use in humans.

Plozalizumab (Anti-CCR2 / CD192)

Synonyms: CCR-2, CD192

Plozalizumab (Anti-CCR2 / CD192) is a specific humanized monoclonal antibody targeting CCR2. Plozalizumab can be used for malignant melanoma research. MW:145.5 KD.

Plozalizumab (Anti-CCR2 / CD192)

Click to purchase the isotype control of Plozalizumab (Anti-CCR2 / CD192)

Quality Control

Batch: A256901 Purity: 99% Protein concentration: 4.13mg/ml Endotoxin Level: <1EU/mg
99

Specificity

Name Citation CCR CCR1 CCR2 CCR3 CCR4 CCR5 CCR9 CCL Others
SB-328437 0
INCB3344 7 mCCR2
RS504393 1
C-021 0
Vercirnon 0
BX471 (ZK-811752) 3
PF-4136309 1
Vicriviroc maleate 1
RS-102895 Hydrochloride 1 human α1a receptor,human α1d receptor,5-HT1a receptor
RS102895 2
TAK-779 0 CXCR3
AZD2098 2
Adaptavir (DAPTA) 3
R243 2
Perillaldehyde 1 NRF2/HO1,ROS,AhR
Cenicriviroc 9 HIV-2,HIV-1
Isuzinaxib (APX-115 free base) 2 TNFα,IL-6,NOX2
SB-297006 4
BMS-813160 2
Bindarit (AF 2838) 25
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Plozalizumab (Anti-CCR2 / CD192) is a specific humanized monoclonal antibody targeting CCR2. Plozalizumab can be used for malignant melanoma research. MW:145.5 KD.

Product Details

CAS No. 1610761-46-0
Molecular Weight 150 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01015560 COMPLETED Drug: anti-CCR2 monoclonal antibody MLN1202 Metastatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific SWOG Cancer Research Network 2010-03 PHASE2

(data from https://clinicaltrials.gov, updated on 2018-08-09)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.